Congress trades and big insider sales, sent the day they're filed. Free.
Open in Telegram
Director, President and CEO · Ovid Therapeutics Inc. · Ovid Therapeutics Inc. — Employee Stock Option (Right to Buy)
Grant or award — administrative, little informational value
No reported dollar value · new position
Disclosed 2 business days after execution (deadline: 2)
1 prior trade recorded in this security
No clustered activity in the dataset
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 9 | Greka AnnaDirector | Grant or award | A | — 130.0K sh | Jun 17, 2026 traded Jun 15, 2026 | |
| 9 | Fitzgerald Kevin JosephDirector | Grant or award | A | $45K 17.6K sh | Apr 9, 2026 traded Apr 7, 2026 | |
| 31 | Alexander Margaret A.Director, President and CEO | Open-market sale | SELL | $17K 11.7K sh | Mar 2, 2026 traded Feb 23, 2026 | |
| 9 | Alexander Margaret A.Director, President and CEO | Grant or award | A | — 890.0K sh | Jan 5, 2026 traded Jan 4, 2026 |
Read directly from the primary public document; every field below is as reported by the filer.
Alexander Margaret A. filed this Form 4 reporting a grant or award of OVID on Feb 26, 2026. It became public on Mar 2, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
No field has changed since this record was first ingested.
No material filings recorded for this issuer.